Search results for "FOV"

showing 10 items of 100 documents

Tenofovir-induced toxicity in renal proximal tubular epithelial cells

2017

OBJECTIVE In-vivo studies suggest that mitochondria is involved in tenofovir (TFV)-induced renal toxicity, but the underlying mechanisms are still unclear. The aim of the present study was to assess the effects of TFV and its prodrug, TFV disoproxil fumarate, on mitochondrial function and cell survival/viability in a renal proximal tubular cell line. DESIGN AND METHODS We evaluated parameters of cellular proliferation/survival (cell count, cell cycle, viability) and mitochondrial function (oxygen consumption, mitochondrial membrane potential, reactive oxygen species production) in NRK-52E cells. Intracellular TFV was measured by HPLC and expression of antioxidant genes was analysed by real-…

0301 basic medicineAnti-HIV AgentsCell Survival030106 microbiologyImmunologyCellOxidative phosphorylationMitochondrionPharmacologyCell Line03 medical and health sciencesmedicineHumansImmunology and AllergyTenofovirCell Proliferationchemistry.chemical_classificationKidneyReactive oxygen speciesCell growthEpithelial Cellsmedicine.diseaseMitochondriaMitochondrial toxicity030104 developmental biologyInfectious Diseasesmedicine.anatomical_structurechemistryIntracellularAIDS
researchProduct

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

2018

Background The CD4/CD8 ratio has been associated with the risk of AIDS and non-AIDS events. We describe trends in immunological parameters in people who underwent a switch to monotherapy or dual therapy, compared to a control group remaining on triple antiretroviral therapy (ART). Methods We included patients in Icona who started a three-drug combination ART regimen from an ART-naïve status and achieved a viral load ≤ 50 copies/mL; they were subsequently switched to another triple or to a mono or double regimen. Standard linear regression at fixed points in time (12-24 months after the switch) and linear mixed model analysis with random intercepts and slopes were used to compare CD4 and CD8…

0301 basic medicineMaleCD4-CD8 Ratiolcsh:MedicineHIV InfectionsCD8-Positive T-LymphocytesCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir; Medicine (all)Cohort Studies0302 clinical medicineEmtricitabineHIV Infection030212 general & internal medicineMedicine (all)General MedicineChronic inflammationCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Medicine (all)Middle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaReverse Transcriptase InhibitorReverse Transcriptase InhibitorsFemalecd4/cd8 ratio; cd8; chronic inflammation; dual therapy; monotherapy; medicine (all)Research Articlemedicine.drugCohort studyHumanAdultmedicine.medical_specialtyDual therapyCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; TenofovirAnti-HIV Agents030106 microbiologyCD4-CD8 RatioEmtricitabineSettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesCD4/CD8 ratioInternal medicineLinear regressionmedicineHumansDual therapyTenofovirbusiness.industrylcsh:RAnti-HIV AgentCD8CD8-Positive T-LymphocyteMonotherapyConfidence intervalRegimenCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; MonotherapyCD8; CD4/CD8 ratio; Chronic inflammation; Monotherapy; Dual therapyCohort StudiebusinessCD8
researchProduct

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients.

2016

The high levels of genetic diversity shown by hepatitis B virus (HBV) are commonly attributed to the low fidelity of its polymerase. However, the rate of spontaneous mutation of human HBV in vivo is currently unknown. Here, based on the evolutionary principle that the population frequency of lethal mutations equals the rate at which they are produced, we have estimated the mutation rate of HBV in vivo by scoring premature stop codons in 621 publicly available, full-length, molecular clone sequences derived from patients. This yielded an estimate of 8.7 × 10-5 spontaneous mutations per nucleotide per cell infection in untreated patients, which should be taken as an upper limit estimate becau…

0301 basic medicineMaleRNA virusesMutation ratelcsh:Medicinemedicine.disease_causeBiochemistryPolymerasesAdefovirFrameshift Mutationlcsh:SciencePathology and laboratory medicineeducation.field_of_studyMultidisciplinaryMicrobial MutationLamivudineMedical microbiologyResistance mutation3. Good healthLamivudineVirusesFemalePathogensSequence AnalysisImmunosuppressive Agentsmedicine.drugResearch ArticleHepatitis B virusSubstitution MutationPopulationOrganophosphonatesBiologyResearch and Analysis MethodsPolymorphism Single NucleotideMicrobiologyFrameshift mutation03 medical and health sciencesHepatitis B ChronicDrug Resistance ViralDNA-binding proteinsmedicineGeneticsHumanseducationMolecular Biology TechniquesSequencing TechniquesMolecular BiologyHepatitis B virusMedicine and health sciencesPoint mutationAdeninelcsh:RViral pathogensOrganismsBiology and Life SciencesProteinsVirologyMolecular biologyHepatitis virusesMicrobial pathogens030104 developmental biologyMutationlcsh:QCloningPLoS ONE
researchProduct

Factors Associated With Weight Gain in People Treated With Dolutegravir.

2020

AbstractBackgroundAn unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens.MethodsAdult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for …

0301 basic medicinemedicine.medical_specialtyWeight gain.HIV metabolic complications030106 microbiologyHIV metabolic complicationTDFEmtricitabineTenofovir alafenamidedolutegravir HIV metabolic complications TAF TDF weight gain.03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAbacavirInternal medicinemedicineMajor Article030212 general & internal medicinebusiness.industryWeight changeLamivudineweight gaindolutegravirInfectious DiseasesAcademicSubjects/MED00290OncologychemistryTAFRilpivirineDolutegravirmedicine.symptombusinessWeight gainmedicine.drugOpen forum infectious diseases
researchProduct

Harnessing Big Data for Communicable Tropical and Sub-Tropical Disorders: Implications From a Systematic Review of the Literature

2018

aim: According to the World Health Organization (WHO), communicable tropical and sub-tropical diseases occur solely, or mainly in the tropics, thriving in hot, and humid conditions. Some of these disorders termed as neglected tropical diseases are par- ticularly overlooked. Communicable tropical/sub-tropical diseases represent a diverse group of communicable disorders occurring in 149 countries, favored by tropical and sub-tropical conditions, affecting more than one billion people and imposing a dramatic societal and economic burden. methods: A systematic review of the extant scholarly literature was carried out, searching in PubMed/MEDLINE and Scopus. The search string used included prope…

030231 tropical medicineBig dataMEDLINEmedicine.disease_causeDengue feverDengueInfodemiologyBig data03 medical and health sciencesZika0302 clinical medicinebig dataEnvironmental healthmedicineSocial media030212 general & internal medicineChikungunyabusiness.industrylcsh:Public aspects of medicineBig data; Chikungunya; Communicable tropical diseases; Dengue; Ebola; Mayaro virus; West Nile virus; Zika; Public Health Environmental and Occupational HealthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthlcsh:RA1-1270big data Zika Ebola Chikungunya West Nile virus dengue Mayaro virus communicable tropical diseasesmedicine.diseasedengueMayaro viruscommunicable tropical diseasesGeographyInfoveillanceEbolaNeglected tropical diseasesChikungunyaCommunicable tropical diseasesPublic HealthSystematic ReviewbusinessWest Nile virusFrontiers in Public Health
researchProduct

Macular sensitivity and structure in idiopathic epiretinal membranes 12 months after surgical treatment

2013

Purpose: To evaluate macular sensitivity (MS) change and its correlation with visual acuity (VA) and Spectral-Domain Optical Coherence Tomography (SD-OCT) in patients with idiopathic epiretinal membrane (ERM) at 3, 6 and 12 months after surgical treatment.Methods: Prospective, monocenter, interventional case series. We included 49 patients (49 eyes) with an idiopathic ERM scheduled for a surgical treatment. Among these patients, 40 were evaluated at 3 and 6 months (M3, M6), and 31 at 12 months (M12) after ERM and internal limiting membrane removal. At each visit a measurement of best-corrected visual acuity (ETDRS), a microperimetry and a SD-OCT were performed for all patients.Results: The …

585 macula/fovea[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologygenetic structurestreatmentsensitivitychirurgietraitement[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory Organs642 perimetry[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organssensibilitémembrane[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Māksliniecisko izteiksmes līdzekļu izpēte Andrē Derēna ainavās vizuālās mākslas stundās 2.klasē

2020

Diplomdarba “Māksliniecisko izteiksmes līdzekļu izpēte Andrē Derēna ainavās vizuālās mākslas stundās 2.klasē” mērķis ir izpētīt un izzināt mākslinieciskās izteiksmes līdzekļus un paņēmienus A.Derēna ainavās un to pielietojuma iespējas vizuālās mākslas stundās 2. klasē. Lai to realizētu tiek veikti vairāki uzdevumi, kuru ietvaros autore pēta un apraksta A.Derēna gleznotajās ainavās izmantotos mākslinieciskās izteiksmes līdzekļus, veicot vizuālās mākslas pamatizglītības standarta un programmas izpēti, pēta jaunākā skolas vecuma skolēnu vecuma attīstības īpatnības, izstrādā un realizē uzdevumu kopu 2.klasei, piemērojot atbilstošas pedagoģiskās metodes, kā arī veic analīzi un apkopo pedagoģiskā…

A. DerēnsfovismsainavasPedagoģijakrāsajaunākais skolas vecums
researchProduct

Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa

2017

Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early experiences from a pilot program for treatment of CHB in Ethiopia. Adults (≥18 years) with CHB were included in a cohort study at St. Paul’s Hospital Millennium Medical College, Addis Ababa, from February 2015. The baseline assessment included liver function tests, viral markers and transient elastography (Fibroscan 402, Echosense, France). Logistic regression models were used to identify predictors of fibrosis. Tenofovir disoproxil fumarate (TDF) was initiated based on the European Association for the Study of the Liver (EASL) criteria, with some modifications. The initial 300 patients …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyCirrhosisPilot ProjectsAntiviral therapyAntiviral Agentslcsh:Infectious and parasitic diseasesCohort StudiesYoung Adult03 medical and health sciencesHepatitis B Chronic0302 clinical medicinePregnancyInterquartile rangeInternal medicinemedicineHumanslcsh:RC109-216Hepatitis B e Antigens030212 general & internal medicinePregnancy Complications InfectiousTenofovirAIDS-Related Opportunistic Infectionsmedicine.diagnostic_testCoinfectionbusiness.industryAlanine TransaminaseMiddle AgedViral LoadHepatitis Bmedicine.diseaseResource-limited settingsInfectious DiseasesHBeAgAfricaImmunologyFemale030211 gastroenterology & hepatologyEthiopiaTransient elastographyLiver function testsbusinessViral loadBiomarkersResearch ArticleCohort study
researchProduct

Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia

2018

Background The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia. Methods At a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence to therapy was measured by …

AdultLiver CirrhosisMalemedicine.medical_specialtyAdolescentEpidemiologylcsh:MedicinePilot ProjectsAntiviral therapymedicine.disease_causeAntiviral AgentsYoung Adult03 medical and health sciencesHepatitis B Chronic0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansPilot program030212 general & internal medicineViral hepatitisTenofovirHepatitis B virusmedicine.diagnostic_testbusiness.industryPublic healthlcsh:RGeneral MedicineMiddle AgedViral Loadmedicine.diseaseResource-limited settingsTreatment Adherence and ComplianceTreatment OutcomeFemale030211 gastroenterology & hepatologyEthiopiaTransient elastographybusinessLiver function testsViral hepatitisBiomarkersFollow-Up StudiesResearch ArticleBMC Medicine
researchProduct

Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study

2019

Abstract Background Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we aimed to assess predictors of mortality in one of the largest CHB cohorts in sub-Saharan Africa. Methods Two-hundred-and-seventy-six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March 18, 2015, and August 1, 2017, were included in this analysis. Patients were followed up until October 1, 2017, and deaths were ascertained through hospital records and telephone interview with relatives. Decompensated cir…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsSurvivalAdolescentEpidemiologyPhysical examinationAntiviral therapyAntiviral AgentsBody Mass Index03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicInterquartile rangeRisk FactorsInternal medicineEpidemiologyMedicineHumansProspective Studieslcsh:RC799-869Prospective cohort studyTenofovirProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryHazard ratioGastroenterologyAge FactorsGeneral MedicineHepatitis BHepatologyMiddle Agedmedicine.diseaseHepatitis BResource-limited settingsSurvival RateVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesislcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyFemaleEthiopiabusinessBody mass indexResearch Article
researchProduct